- Home
- IBIO vs VIDA Comparison
IBIO vs VIDA Comparison
Compare IBIO & VIDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | VIDA |
|---|---|---|
| Founded | 2008 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.0M | 64.7M |
| IPO Year | 2009 | 2026 |
Fundamental Metrics
Financial Performance| Metric | IBIO | VIDA |
|---|---|---|
| Price | $0.76 | $1.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $5.69 | N/A |
| AVG Volume (30 Days) | ★ 858.9K | 47.1K |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $1.06 |
| 52 Week High | $3.82 | $4.25 |
Technical Indicators
Market Signals| Indicator | IBIO | VIDA |
|---|---|---|
| Relative Strength Index (RSI) | 19.34 | 21.18 |
| Support Level | N/A | N/A |
| Resistance Level | $1.52 | $2.79 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 6.77 | 8.96 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.